ISIS-SMNRx: Extension study started

Isis began the open-label, international SHINE extension study to evaluate 12 mg intrathecal ISIS-SMNRx in about 274 patients who have completed the double-blind, sham-controlled Phase III ENDEAR or CHERISH trials. In SHINE, infants who enrolled in ENDEAR will receive ISIS-SMNRx every 4 months and non-ambulatory children who enrolled in CHERISH will receive the product every 6 months. Data from ENDEAR and CHERISH are expected late 2016 or early 2017. ...